Search results
Found 16134 matches for
The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.
EXTEND Newsletter: Issue 1, January 2023
Issue #1 of the quarterly newsletter for the EXTEND Study
According to EXTEND-InG
Members of the EXTEND Involvement Group on why the EXTEND project is important and why they've got involved.